Sangamo Therapeutics (SGMO) Expected to Announce Earnings on Thursday

Sangamo Therapeutics (NASDAQ:SGMO) is projected to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $31.68 million for the quarter.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The business had revenue of $6.44 million during the quarter, compared to analyst estimates of $7.90 million. Sangamo Therapeutics had a negative net margin of 124.61% and a negative return on equity of 345.98%. On average, analysts expect Sangamo Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Price Performance

Shares of NASDAQ:SGMO opened at $0.54 on Tuesday. Sangamo Therapeutics has a 1-year low of $0.41 and a 1-year high of $3.18. The stock has a market cap of $124.75 million, a P/E ratio of -1.37 and a beta of 1.18. The firm has a fifty day moving average price of $0.51 and a 200 day moving average price of $0.74.

Analyst Upgrades and Downgrades

SGMO has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, June 24th. Barclays dropped their target price on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 14th. Finally, Wall Street Zen downgraded Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $4.50.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.